Novo Nordisk said Mylan’s proposed generic version of an injectable treatment for diabetes infringes seven patents related to the blockbuster drug Victoza.
- Novo is seeking a court order blocking copies until after the patents have expired, and to collect cash compensation if copies are made before then, according to complaint filed Tuesday in federal court in Wilmington, Delaware
- Victoza had U.S. sales of 18.1 billion Danish kroner ($2.7 billion) in 2018, 16.2% of Novo’s revenue, according to data compiled by Bloomberg
- Patents expire in July 2021, December 2022, February and December 2023, November 2024, February 2026 and March 2033: FDA...
For more stories, analysis and expertiseOR Request Trial